Overview

* Rapid Micro Biosystems ( RPID ) Q3 revenue grows 3% to $7.8 mln, slightly beating expectations

* Net loss for Q3 was $11.5 mln, missing analyst expectations

Outlook

* Company raises full-year 2025 revenue guidance to at least $33 mln

* Company expects meaningful contribution from multi-system order in Q4 2025

* Company sees continued growth in 2026 and beyond

Result Drivers

* RECURRING REVENUE GROWTH - Recurring revenue increased 32% due to record consumable sales, contributing significantly to overall revenue growth

* RECORD CUSTOMER ORDER - Largest multi-system order from a Top 20 global biopharma customer to automate manufacturing network, supporting future growth

* GROSS MARGIN IMPROVEMENT - Gross margin improved by 70 basis points to 9% compared to Q3 2024, despite flat product revenue

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Slight $7.80 $7.75

Revenue Beat* mln mln (4

Analysts

)

Q3 EPS -$0.26

Q3 Net Miss -$11.50 -$10.60

Income mln mln (3

Analysts

)

Q3 $12.10

Operatin mln

g

Expenses

*Applies to a deviation of less than 1%; not applicable for per-share numbers.

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

* Wall Street's median 12-month price target for Rapid Micro Biosystems Inc ( RPID ) is $8.00, about 65.6% above its November 6 closing price of $2.75

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)